固定されたツイート

We are excited to announce that Novo Nordisk is expanding patient access to Wegovy® (semaglutide) by enabling LifeMD to work directly through NovoCare® Pharmacy.
“By embedding direct access to Wegovy® via NovoCare® Pharmacy into our platform, we’re enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD’s position as a leader in delivering comprehensive, technology-enabled obesity care. With this offering, we’ve taken another important step in delivering on our promise of reducing friction in the patient journey—ensuring more patients can access life-changing medications like Wegovy® without unnecessary delays or barriers.”
Read more about this significant milestone for LifeMD and the patients we serve.
LifeMD.com
ir.lifemd.com/press-release-…
English
